ClinVar Genomic variation as it relates to human health
NM_000492.4(CFTR):c.3737C>T (p.Thr1246Ile)
The aggregate germline classification for this variant, typically for a monogenic or Mendelian disorder as in the ACMG/AMP guidelines, or for response to a drug. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the aggregate classification.
Stars represent the aggregate review status, or the level of review supporting the aggregate germline classification for this VCV record. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the review status. The number of submissions which contribute to this review status is shown in parentheses.
No data submitted for somatic clinical impact
No data submitted for oncogenicity
Variant Details
- Identifiers
-
NM_000492.4(CFTR):c.3737C>T (p.Thr1246Ile)
Variation ID: 53799 Accession: VCV000053799.65
- Type and length
-
single nucleotide variant, 1 bp
- Location
-
Cytogenetic: 7q31.2 7: 117642457 (GRCh38) [ NCBI UCSC ] 7: 117282511 (GRCh37) [ NCBI UCSC ]
- Timeline in ClinVar
-
First in ClinVar Help The date this variant first appeared in ClinVar with each type of classification.
Last submission Help The date of the most recent submission for each type of classification for this variant.
Last evaluated Help The most recent date that a submitter evaluated this variant for each type of classification.
Germline Aug 5, 2018 Oct 8, 2024 Jan 30, 2024 - HGVS
-
Nucleotide Protein Molecular
consequenceNM_000492.4:c.3737C>T MANE Select Help Transcripts from the Matched Annotation from the NCBI and EMBL-EBI (MANE) collaboration.
NP_000483.3:p.Thr1246Ile missense NC_000007.14:g.117642457C>T NC_000007.13:g.117282511C>T NG_016465.4:g.181674C>T LRG_663:g.181674C>T LRG_663t1:c.3737C>T LRG_663p1:p.Thr1246Ile - Protein change
- T1246I
- Other names
- -
- Canonical SPDI
- NC_000007.14:117642456:C:T
-
Functional
consequence HelpThe effect of the variant on RNA or protein function, based on experimental evidence from submitters.
- -
-
Global minor allele
frequency (GMAF) HelpThe global minor allele frequency calculated by the 1000 Genomes Project. The minor allele at this location is indicated in parentheses and may be different from the allele represented by this VCV record.
- -
-
Allele frequency
Help
The frequency of the allele represented by this VCV record.
-
Trans-Omics for Precision Medicine (TOPMed) 0.00000
Exome Aggregation Consortium (ExAC) 0.00001
The Genome Aggregation Database (gnomAD) 0.00001
- Links
Genes
Gene | OMIM | ClinGen Gene Dosage Sensitivity Curation |
Variation Viewer
Help
Links to Variation Viewer, a genome browser to view variation data from NCBI databases. |
Related variants | ||
---|---|---|---|---|---|---|
HI score
Help
The haploinsufficiency score for the gene, curated by ClinGen’s Dosage Sensitivity Curation task team. |
TS score
Help
The triplosensitivity score for the gene, curated by ClinGen’s Dosage Sensitivity Curation task team. |
Within gene
Help
The number of variants in ClinVar that are contained within this gene, with a link to view the list of variants. |
All
Help
The number of variants in ClinVar for this gene, including smaller variants within the gene and larger CNVs that overlap or fully contain the gene. |
|||
CFTR | - | - |
GRCh38 GRCh37 |
3825 | 5200 |
Conditions - Germline
Condition
Help
The condition for this variant-condition (RCV) record in ClinVar. |
Classification
Help
The aggregate germline classification for this variant-condition (RCV) record in ClinVar. The number of submissions that contribute to this aggregate classification is shown in parentheses. (# of submissions) |
Review status
Help
The aggregate review status for this variant-condition (RCV) record in ClinVar. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the review status. |
Last evaluated
Help
The most recent date that a submitter evaluated this variant for the condition. |
Variation/condition record
Help
The RCV accession number, with most recent version number, for the variant-condition record, with a link to the RCV web page. |
---|---|---|---|---|
Pathogenic/Likely pathogenic (7) |
criteria provided, multiple submitters, no conflicts
|
Oct 8, 2023 | RCV000668850.28 | |
Likely pathogenic (1) |
criteria provided, single submitter
|
Jul 9, 2020 | RCV001811328.13 | |
CFTR-related disorder
|
Pathogenic (2) |
criteria provided, single submitter
|
Jan 18, 2021 | RCV002281555.11 |
Likely pathogenic (1) |
criteria provided, single submitter
|
Jan 30, 2024 | RCV003474588.2 |
Submissions - Germline
Classification
Help
The submitted germline classification for each SCV record. (Last evaluated) |
Review status
Help
Stars represent the review status, or the level of review supporting the submitted (SCV) record. This value is calculated by NCBI based on data from the submitter. Read our rules for calculating the review status. This column also includes a link to the submitter’s assertion criteria if provided, and the collection method. (Assertion criteria) |
Condition
Help
The condition for the classification, provided by the submitter for this submitted (SCV) record. This column also includes the affected status and allele origin of individuals observed with this variant. |
Submitter
Help
The submitting organization for this submitted (SCV) record. This column also includes the SCV accession and version number, the date this SCV first appeared in ClinVar, and the date that this SCV was last updated in ClinVar. |
More information
Help
This column includes more information supporting the classification, including citations, the comment on classification, and detailed evidence provided as observations of the variant by the submitter. |
|
---|---|---|---|---|---|
Pathogenic
(Jan 18, 2021)
|
criteria provided, single submitter
Method: curation
|
CFTR-related disorders
Affected status: yes
Allele origin:
germline
|
CFTR-France
Accession: SCV002570019.1
First in ClinVar: Sep 10, 2022 Last updated: Sep 10, 2022 |
|
|
Pathogenic
(Mar 31, 2022)
|
criteria provided, single submitter
Method: clinical testing
|
Cystic fibrosis
Affected status: unknown
Allele origin:
germline
|
Ambry Genetics
Accession: SCV002622539.2
First in ClinVar: Nov 29, 2022 Last updated: May 01, 2024 |
Comment:
The p.T1246I pathogenic mutation (also known as c.3737C>T), located in coding exon 23 of the CFTR gene, results from a C to T substitution at … (more)
The p.T1246I pathogenic mutation (also known as c.3737C>T), located in coding exon 23 of the CFTR gene, results from a C to T substitution at nucleotide position 3737. The threonine at codon 1246 is replaced by isoleucine, an amino acid with similar properties. This alteration has been reported as compound heterozygous with another CFTR alteration in several individuals with cystic fibrosis or CFTR-related disorders (Claustres M et al. Hum. Mutat., 2000;16:143-56; Goubau C et al. Thorax, 2009 Aug;64:683-91; Sermet-Gaudelus I et al. Am. J. Respir. Crit. Care Med., 2010 Oct;182:929-36; Masica DL et al. Hum. Mol. Genet., 2015 Apr;24:1908-17). This position has been shown to be important in binding ATP for chloride channel gating, however, the T1246I alteration was not specifically evaluated (Vergani P et al. Nature, 2005 Feb;433:876-80). This variant has been reported in multiple individuals with an elevated sweat chloride level in The Clinical and Functional TRanslation of CFTR (CFTR2) database (available at http://cftr2.org. Accessed 03/29/2022). In CFBE cells, this variant showed reduced CFTR function compared to wild type (Raraigh KS et al. Am. J. Hum. Genet., 2018 06;102:1062-1077; Han ST et al. JCI Insight, 2018 Jul;3(14):pii 121159). The p.T1246I alteration has been reported as a variant of varying clinical consequences (VVCC) (Sosnay PR et al. Pediatr. Clin. North Am., 2016 08;63:585-98; Raraigh KS et al. Am. J. Hum. Genet., 2018 06;102:1062-1077). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. (less)
|
|
Likely pathogenic
(Jan 30, 2024)
|
criteria provided, single submitter
Method: clinical testing
|
Bronchiectasis with or without elevated sweat chloride 1
Affected status: unknown
Allele origin:
unknown
|
Baylor Genetics
Accession: SCV004213387.2
First in ClinVar: Dec 30, 2023 Last updated: Jun 17, 2024 |
|
|
Pathogenic
(Apr 27, 2020)
|
criteria provided, single submitter
Method: clinical testing
|
Cystic fibrosis
Affected status: unknown
Allele origin:
germline
|
Johns Hopkins Genomics, Johns Hopkins University
Accession: SCV001425315.1
First in ClinVar: Aug 01, 2020 Last updated: Aug 01, 2020 |
Comment:
CFTR variant associated with varying clinical consequence. See www.CFTR2.org for phenotype information.
|
|
Likely pathogenic
(Jul 09, 2020)
|
criteria provided, single submitter
Method: clinical testing
|
not provided
Affected status: unknown
Allele origin:
germline
|
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Accession: SCV001474386.1
First in ClinVar: Jan 26, 2021 Last updated: Jan 26, 2021 |
Comment:
The CFTR c.3737C>T; p.Thr1246Ile variant (rs397508600) is reported in the literature in the compound heterozygous state with a different pathogenic variant in individuals affected with … (more)
The CFTR c.3737C>T; p.Thr1246Ile variant (rs397508600) is reported in the literature in the compound heterozygous state with a different pathogenic variant in individuals affected with cystic fibrosis, a CFTR-related disorder, or borderline sweat chloride levels with no other significant symptoms (Claustres 2000, El-Seedy 2012, Goubau 2009, Masica 2015, Sermet-Gaudelus 2010, Sosnay 2017). This variant is reported in ClinVar (Variation ID: 53799), and is only observed on one allele in the Genome Aggregation Database, indicating it is not a common polymorphism. The threonine at codon 1246 is highly conserved, and computational analyses (SIFT, PolyPhen-2) predict that this variant is deleterious. In vitro functional analyses of the variant protein demonstrate 13% of wild-type function, consistent with an intermediate effect (Raraigh 2018). Based on available information, this variant is considered to be likely pathogenic with variable clinical consequences. References: Claustres M et al. Spectrum of CFTR mutations in cystic fibrosis and in congenital absence of the vas deferens in France. Hum Mutat. 2000;16(2):143-156. El-Seedy A et al. CFTR mutation combinations producing frequent complex alleles with different clinical and functional outcomes. Hum Mutat. 2012;33(11):1557-1565. Goubau C et al. Phenotypic characterisation of patients with intermediate sweat chloride values: towards validation of the European diagnostic algorithm for cystic fibrosis. Thorax. 2009;64(8):683-691. Masica DL et al. Missense variants in CFTR nucleotide-binding domains predict quantitative phenotypes associated with cystic fibrosis disease severity. Hum Mol Genet. 2015;24(7):1908-1917. Raraigh KS et al. Functional Assays Are Essential for Interpretation of Missense Variants Associated with Variable Expressivity. Am J Hum Genet. 2018;102(6):1062-1077. Sermet-Gaudelus I et al. Clinical phenotype and genotype of children with borderline sweat test and abnormal nasal epithelial chloride transport. Am J Respir Crit Care Med. 2010;182(7):929-936. Sosnay PR et al. Diagnosis of Cystic Fibrosis in Nonscreened Populations. J Pediatr. 2017;181S:S52-S57.e2. References: Claustres M et al. Spectrum of CFTR mutations in cystic fibrosis and in congenital absence of the vas deferens in France. Hum Mutat. 2000;16(2):143-156. El-Seedy A et al. CFTR mutation combinations producing frequent complex alleles with different clinical and functional outcomes. Hum Mutat. 2012;33(11):1557-1565. Goubau C et al. Phenotypic characterisation of patients with intermediate sweat chloride values: towards validation of the European diagnostic algorithm for cystic fibrosis. Thorax. 2009;64(8):683-691. Masica DL et al. Missense variants in CFTR nucleotide-binding domains predict quantitative phenotypes associated with cystic fibrosis disease severity. Hum Mol Genet. 2015;24(7):1908-1917. Raraigh KS et al. Functional Assays Are Essential for Interpretation of Missense Variants Associated with Variable Expressivity. Am J Hum Genet. 2018;102(6):1062-1077. Sermet-Gaudelus I et al. Clinical phenotype and genotype of children with borderline sweat test and abnormal nasal epithelial chloride transport. Am J Respir Crit Care Med. 2010;182(7):929-936. Sosnay PR, White TB, Farrell PM, et al. Diagnosis of Cystic Fibrosis in Nonscreened Populations. J Pediatr. 2017;181S:S52-S57.e2. (less)
|
|
Likely pathogenic
(Sep 05, 2022)
|
criteria provided, single submitter
Method: curation
|
Cystic fibrosis
Affected status: yes
Allele origin:
unknown
|
Institute of Human Genetics, University of Leipzig Medical Center
Accession: SCV002573863.1
First in ClinVar: Sep 24, 2022 Last updated: Sep 24, 2022 |
Comment:
This variant was identified in 1 patient with a clinically confirmed diagnosis of cystic fibrosis. The variant was classified in the context of a project … (more)
This variant was identified in 1 patient with a clinically confirmed diagnosis of cystic fibrosis. The variant was classified in the context of a project re-classifying variants in the German Cystic Fibrosis Registry (Muko.e.V.). Link: https://www.muko.info/angebote/qualitaetsmanagement/register/cf-einrichtungen/mukoweb. Criteria applied: PS3_SUP, PM2_SUP, PM3_STR, PP3 (less)
Number of individuals with the variant: 1
|
|
Pathogenic
(Oct 26, 2022)
|
criteria provided, single submitter
Method: clinical testing
|
Cystic fibrosis
Affected status: unknown
Allele origin:
germline
|
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Accession: SCV000919178.2
First in ClinVar: Jun 02, 2019 Last updated: Nov 19, 2022 |
Comment:
Variant summary: CFTR c.3737C>T (p.Thr1246Ile) results in a non-conservative amino acid change located in the ABC transporter-like, ATP-binding (IPR003439) and AAA+ ATPase (IPR003593) domains of … (more)
Variant summary: CFTR c.3737C>T (p.Thr1246Ile) results in a non-conservative amino acid change located in the ABC transporter-like, ATP-binding (IPR003439) and AAA+ ATPase (IPR003593) domains of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 4e-06 in 250992 control chromosomes (gnomAD). c.3737C>T has been reported in the literature as a compound heterozygous genotype (mostly in trans with the known pathogenic variant p.Phe508del) in multiple individuals affected with Non-Classic Cystic Fibrosis related phenotypes and has been linked to varying clinical consequences; sweat chloride values were reported to be in the intermediate range for at least some of these individuals (example: Claustres_2000, Goubau_2009, El-Seedy_2012, Sosnay_2017_McCague_2019). These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in 10%-<30% of normal CFTR activity (Han_2018, Raraigh_2018). Seven clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 and classified it as VUS (n=2), likely pathogenic (n=2) and pathogenic (n=3). Based on the evidence outlined above, the variant was classified as pathogenic, with varying clinical consequences. (less)
|
|
Pathogenic
(Mar 11, 2023)
|
criteria provided, single submitter
Method: clinical testing
|
Cystic fibrosis
Affected status: yes
Allele origin:
unknown
|
Mendelics
Accession: SCV000886147.4
First in ClinVar: Aug 05, 2018 Last updated: Mar 18, 2023 |
|
|
Pathogenic
(Oct 08, 2023)
|
criteria provided, single submitter
Method: clinical testing
|
Cystic fibrosis
Affected status: unknown
Allele origin:
germline
|
Labcorp Genetics (formerly Invitae), Labcorp
Accession: SCV001590786.5
First in ClinVar: May 10, 2021 Last updated: Feb 20, 2024 |
Comment:
This sequence change replaces threonine, which is neutral and polar, with isoleucine, which is neutral and non-polar, at codon 1246 of the CFTR protein (p.Thr1246Ile). … (more)
This sequence change replaces threonine, which is neutral and polar, with isoleucine, which is neutral and non-polar, at codon 1246 of the CFTR protein (p.Thr1246Ile). This variant is present in population databases (rs397508600, gnomAD 0.0009%). This missense change has been observed in individuals with cystic fibrosis, and intermediate sweat chloride results (PMID: 10923036, 19318346, 20538955, 22678879, 28129813). ClinVar contains an entry for this variant (Variation ID: 53799). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt CFTR protein function. Experimental studies have shown that this missense change affects CFTR function (PMID: 29805046, 30046002). For these reasons, this variant has been classified as Pathogenic. (less)
|
|
Likely pathogenic
(Jan 18, 2024)
|
no assertion criteria provided
Method: clinical testing
|
CFTR-related condition
Affected status: unknown
Allele origin:
germline
|
PreventionGenetics, part of Exact Sciences
Accession: SCV004730576.2
First in ClinVar: Mar 16, 2024 Last updated: Oct 08, 2024 |
Comment:
The CFTR c.3737C>T variant is predicted to result in the amino acid substitution p.Thr1246Ile. This variant, along with a second CFTR variant, has been reported … (more)
The CFTR c.3737C>T variant is predicted to result in the amino acid substitution p.Thr1246Ile. This variant, along with a second CFTR variant, has been reported in individuals with cystic fibrosis (CF) and cystic fibrosis-related disorders (CF-RD), including congenital bilateral absence of the vas deferens (Table 4, Claustres et al. 2000. PubMed ID: 10923036; Table 1, El-Seedy et al. 2012. PubMed ID: 22678879; Sosnay et al. 2017. PubMed ID: 28129813; CFTR-France database, https://cftr.iurc.montp.inserm.fr/cgi-bin/affiche.cgi?variant=c.3737C%3ET). This variant has also been reported in in the CFTR2 Database in more than 20 patients as a variant of varying clinical consequence and has been reported in the heterozygous state in a study of individuals with COPD or asthma (Supplementary Table 1, Saferali et al. 2022. PubMed ID: 34996830; https://cftr2.org/mutation/general/T1246I/). In vitro experimental studies suggest this variant reduces CFTR function to 10%–20% compared to control (Raraigh et al. 2018. PubMed ID: 29805046; Han et al. 2018. PubMed ID: 30046002). An alternate nucleotide substitution affecting the same amino acid (p.Thr1246Ala), has been reported in an individual with male infertility (Table 2, Li et al. 2022. PubMed ID: 34931337). This variant is reported in 0.00088% of alleles in individuals of European (non-Finnish) descent in gnomAD. Taken together, the c.3737C>T (p.Thr1246Ile) variant is interpreted as likely pathogenic. (less)
|
|
Uncertain significance
(Aug 25, 2017)
|
Flagged submission
flagged submission
Method: clinical testing
Reason: Outlier claim with insufficient supporting evidence
Source: ClinGen
|
Cystic fibrosis
Affected status: unknown
Allele origin:
unknown
|
Counsyl
Accession: SCV000793522.1
First in ClinVar: Aug 05, 2018 Last updated: Aug 05, 2018 |
|
|
click to load more click to collapse | |||||
Flagged submissions do not contribute to the aggregate classification or review status for the variant. Learn more |
Germline Functional Evidence
There is no functional evidence in ClinVar for this variation. If you have generated functional data for this variation, please consider submitting that data to ClinVar. |
Citations for germline classification of this variant
HelpTitle | Author | Journal | Year | Link |
---|---|---|---|---|
Correlating Cystic Fibrosis Transmembrane Conductance Regulator Function with Clinical Features to Inform Precision Treatment of Cystic Fibrosis. | McCague AF | American journal of respiratory and critical care medicine | 2019 | PMID: 30888834 |
Residual function of cystic fibrosis mutants predicts response to small molecule CFTR modulators. | Han ST | JCI insight | 2018 | PMID: 30046002 |
Functional Assays Are Essential for Interpretation of Missense Variants Associated with Variable Expressivity. | Raraigh KS | American journal of human genetics | 2018 | PMID: 29805046 |
Diagnosis of Cystic Fibrosis in Nonscreened Populations. | Sosnay PR | The Journal of pediatrics | 2017 | PMID: 28129813 |
Missense variants in CFTR nucleotide-binding domains predict quantitative phenotypes associated with cystic fibrosis disease severity. | Masica DL | Human molecular genetics | 2015 | PMID: 25489051 |
CFTR mutation combinations producing frequent complex alleles with different clinical and functional outcomes. | El-Seedy A | Human mutation | 2012 | PMID: 22678879 |
Clinical phenotype and genotype of children with borderline sweat test and abnormal nasal epithelial chloride transport. | Sermet-Gaudelus I | American journal of respiratory and critical care medicine | 2010 | PMID: 20538955 |
Phenotypic characterisation of patients with intermediate sweat chloride values: towards validation of the European diagnostic algorithm for cystic fibrosis. | Goubau C | Thorax | 2009 | PMID: 19318346 |
CFTR channel opening by ATP-driven tight dimerization of its nucleotide-binding domains. | Vergani P | Nature | 2005 | PMID: 15729345 |
Spectrum of CFTR mutations in cystic fibrosis and in congenital absence of the vas deferens in France. | Claustres M | Human mutation | 2000 | PMID: 10923036 |
Text-mined citations for rs397508600 ...
HelpRecord last updated Oct 27, 2024
This date represents the last time this VCV record was updated. The update may be due to an update to one of the included submitted records (SCVs), or due to an update that ClinVar made to the variant such as adding HGVS expressions or a rs number. So this date may be different from the date of the “most recent submission” reported at the top of this page.